Trials / Completed
CompletedNCT00447564
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 163 (actual)
- Sponsor
- Titan Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Probuphine | 4 implants |
| DRUG | placebo | 4 implants |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2007-03-14
- Last updated
- 2018-12-31
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00447564. Inclusion in this directory is not an endorsement.